As of 2025-07-11, the EV/EBITDA ratio of Sigilon Therapeutics, Inc. (SGTX) is -0.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGTX's latest enterprise value is 32.33 mil USD. SGTX's TTM EBITDA according to its financial statements is -34.77 mil USD. Dividing these 2 quantities gives us the above SGTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.2x - 13.5x | 13.1x |
| Forward P/E multiples | 17.3x - 32.6x | 20.8x |
| Fair Price | (229.85) - (176.48) | (224.73) |
| Upside | -1122.9% - -885.4% | -1100.1% |
| Date | EV/EBITDA |